Literature DB >> 33707304

Type 2 Diabetes Subgroups, Risk for Complications, and Differential Effects Due to an Intensive Lifestyle Intervention.

Michael P Bancks1, Haiying Chen2, Ashok Balasubramanyam3, Alain G Bertoni2, Mark A Espeland2, Steven E Kahn4, Scott Pilla5, Elizabeth Vaughan3, Lynne E Wagenknecht.   

Abstract

OBJECTIVE: We reevaluated the Action for Health in Diabetes (Look AHEAD) intervention, incorporating diabetes subgroups, to identify whether intensive lifestyle intervention (ILI) is associated with differential risk for cardiovascular disease (CVD) by diabetes subgroup. RESEARCH DESIGN AND METHODS: In the Look AHEAD trial, 5,145 participants, aged 45-76 years, with type 2 diabetes (T2D) and overweight or obesity were randomly assigned to 10 years of ILI or a control condition of diabetes support and education. The ILI focused on weight loss through decreased caloric intake and increased physical activity. To characterize diabetes subgroups, we applied k-means clustering to data on age of diabetes diagnosis, BMI, waist circumference, and glycated hemoglobin. We examined whether relative intervention effects on the trial's prespecified CVD outcomes varied among diabetes subgroups.
RESULTS: We characterized four subgroups related to older age at diabetes onset (42% of sample), poor glucose control (14%), severe obesity (24%), and younger age at diabetes onset (20%). We observed interactions (all P < 0.05) between intervention and diabetes subgroups for three separate composite cardiovascular outcomes. Randomization to ILI was associated with increased risk for each cardiovascular outcome only among the poor-glucose-control subgroup (hazard ratio >1.32). Among the three other diabetes subgroups, ILI was not associated with increased risk for CVD.
CONCLUSIONS: Among overweight and obese adults with T2D, a lifestyle intervention was associated with differential risk for CVD that was dependent on diabetes subgroup. Diabetes subgroups may be important to identify the patients who would achieve benefit and avoid harm from an ILI.
© 2021 by the American Diabetes Association.

Entities:  

Mesh:

Year:  2021        PMID: 33707304      PMCID: PMC8132317          DOI: 10.2337/dc20-2372

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  23 in total

1.  Impact of an 8-Year Intensive Lifestyle Intervention on an Index of Multimorbidity.

Authors:  Mark A Espeland; Sarah A Gaussoin; Judy Bahnson; Elizabeth M Vaughan; William C Knowler; Felicia R Simpson; Helen P Hazuda; Karen C Johnson; Medha N Munshi; Mace Coday; Xavier Pi-Sunyer
Journal:  J Am Geriatr Soc       Date:  2020-07-17       Impact factor: 5.562

2.  Multiple imputation of discrete and continuous data by fully conditional specification.

Authors:  Stef van Buuren
Journal:  Stat Methods Med Res       Date:  2007-06       Impact factor: 3.021

3.  Epidemiology of diabetes phenotypes and prevalent cardiovascular risk factors and diabetes complications in the National Health and Nutrition Examination Survey 2003-2014.

Authors:  Michael P Bancks; Ramon Casanova; Edward W Gregg; Alain G Bertoni
Journal:  Diabetes Res Clin Pract       Date:  2019-11-06       Impact factor: 5.602

4.  Introduction: Standards of Medical Care in Diabetes-2020.

Authors: 
Journal:  Diabetes Care       Date:  2020-01       Impact factor: 19.112

5.  Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study.

Authors:  Oana P Zaharia; Klaus Strassburger; Alexander Strom; Gidon J Bönhof; Yanislava Karusheva; Sofia Antoniou; Kálmán Bódis; Daniel F Markgraf; Volker Burkart; Karsten Müssig; Jong-Hee Hwang; Olof Asplund; Leif Groop; Emma Ahlqvist; Jochen Seissler; Peter Nawroth; Stefan Kopf; Sebastian M Schmid; Michael Stumvoll; Andreas F H Pfeiffer; Stefan Kabisch; Sergey Tselmin; Hans U Häring; Dan Ziegler; Oliver Kuss; Julia Szendroedi; Michael Roden
Journal:  Lancet Diabetes Endocrinol       Date:  2019-07-22       Impact factor: 32.069

Review 6.  The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it.

Authors:  Thomas A Wadden; Delia Smith West; Linda Delahanty; John Jakicic; Jack Rejeski; Don Williamson; Robert I Berkowitz; David E Kelley; Christine Tomchee; James O Hill; Shiriki Kumanyika
Journal:  Obesity (Silver Spring)       Date:  2006-05       Impact factor: 5.002

7.  Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes.

Authors:  Donna H Ryan; Mark A Espeland; Gary D Foster; Steven M Haffner; Van S Hubbard; Karen C Johnson; Steven E Kahn; William C Knowler; Susan Z Yanovski
Journal:  Control Clin Trials       Date:  2003-10

8.  Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial.

Authors:  Xavier Pi-Sunyer; George Blackburn; Frederick L Brancati; George A Bray; Renee Bright; Jeanne M Clark; Jeffrey M Curtis; Mark A Espeland; John P Foreyt; Kathryn Graves; Steven M Haffner; Barbara Harrison; James O Hill; Edward S Horton; John Jakicic; Robert W Jeffery; Karen C Johnson; Steven Kahn; David E Kelley; Abbas E Kitabchi; William C Knowler; Cora E Lewis; Barbara J Maschak-Carey; Brenda Montgomery; David M Nathan; Jennifer Patricio; Anne Peters; J Bruce Redmon; Rebecca S Reeves; Donna H Ryan; Monika Safford; Brent Van Dorsten; Thomas A Wadden; Lynne Wagenknecht; Jacqueline Wesche-Thobaben; Rena R Wing; Susan Z Yanovski
Journal:  Diabetes Care       Date:  2007-03-15       Impact factor: 19.112

9.  History of Cardiovascular Disease, Intensive Lifestyle Intervention, and Cardiovascular Outcomes in the Look AHEAD Trial.

Authors:  Cora E Lewis; John P Bantle; Alain G Bertoni; George Blackburn; Frederick L Brancati; George A Bray; Lawrence J Cheskin; Jeffrey M Curtis; Caitlin Egan; Mary Evans; John P Foreyt; Siran Ghazarian; Bethany Barone Gibbs; Stephen P Glasser; Edward W Gregg; Helen P Hazuda; Louise Hesson; James O Hill; Edward S Horton; Van S Hubbard; John M Jakicic; Robert W Jeffery; Karen C Johnson; Steven E Kahn; Abbas E Kitabchi; Dalane Kitzman; William C Knowler; Edward Lipkin; Sara Michaels; Maria G Montez; David M Nathan; Ebenezer Nyenwe; Jennifer Patricio; Anne Peters; Xavier Pi-Sunyer; Henry Pownall; David M Reboussin; Donna H Ryan; Thomas A Wadden; Lynne E Wagenknecht; Holly Wyatt; Rena R Wing; Susan Z Yanovski
Journal:  Obesity (Silver Spring)       Date:  2020-01-03       Impact factor: 5.002

10.  Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data.

Authors:  John M Dennis; Beverley M Shields; William E Henley; Angus G Jones; Andrew T Hattersley
Journal:  Lancet Diabetes Endocrinol       Date:  2019-04-29       Impact factor: 44.867

View more
  4 in total

1.  Clinical variable-based cluster analysis identifies novel subgroups with a distinct genetic signature, lipidomic pattern and cardio-renal risks in Asian patients with recent-onset type 2 diabetes.

Authors:  Jiexun Wang; Jian-Jun Liu; Resham L Gurung; Sylvia Liu; Janus Lee; Yiamunaa M; Keven Ang; Yi Ming Shao; Justin I-Shing Tang; Peter I Benke; Federico Torta; Markus R Wenk; Subramaniam Tavintharan; Wern Ee Tang; Chee Fang Sum; Su Chi Lim
Journal:  Diabetologia       Date:  2022-06-28       Impact factor: 10.460

Review 2.  Precision nutrition in diabetes: when population-based dietary advice gets personal.

Authors:  Jordi Merino
Journal:  Diabetologia       Date:  2022-05-20       Impact factor: 10.460

Review 3.  Toward an Improved Classification of Type 2 Diabetes: Lessons From Research into the Heterogeneity of a Complex Disease.

Authors:  Maria J Redondo; Ashok Balasubramanyam
Journal:  J Clin Endocrinol Metab       Date:  2021-11-19       Impact factor: 6.134

Review 4.  A novel diabetes typology: towards precision diabetology from pathogenesis to treatment.

Authors:  Christian Herder; Michael Roden
Journal:  Diabetologia       Date:  2022-01-04       Impact factor: 10.460

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.